Lista de obras - Biagio Ricciuti - Dominio Público Uruguay

A comparison of mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients

artículo científico publicado en 2019

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

artículo científico publicado en 2019

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

artículo científico publicado en 2018

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

article

Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

artículo científico publicado en 2016

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence

article

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

scientific article published on 01 October 2020

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

scientific article published on 01 December 2019

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status

artículo científico publicado en 2013

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

artículo científico publicado en 2019

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

artículo científico publicado en 2020

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

scientific article published on 21 February 2019

Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking

artículo científico publicado en 2015

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

scientific article published on 01 August 2018

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient

artículo científico publicado en 2016

Emerging Biomarkers in the Era of Personalized Cancer Medicine

scientific article published on 14 August 2019

Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications

artículo científico publicado en 2017

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy

artículo científico publicado en 2017

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report.

artículo científico publicado en 2015

Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy

artículo científico publicado en 2017

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?

artículo científico publicado en 2017

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.

artículo científico publicado en 2018

Future options for ALK-positive non-small cell lung cancer.

artículo científico publicado en 2015

High density lipoprotein cholesterol and cancer: Marker or causative?

artículo científico publicado en 2018

High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art.

artículo científico publicado en 2018

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib

artículo científico publicado en 2018

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

artículo científico publicado en 2016

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

artículo científico publicado en 2020

Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer

scientific article published on 24 April 2020

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

artículo científico publicado en 2018

KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

artículo científico publicado en 2018

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer

artículo científico publicado en 2017

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

artículo científico publicado en 2020

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

artículo científico publicado en 2016

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient

artículo científico publicado en 2017

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

artículo científico publicado en 2018

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

artículo científico publicado en 2016

Melanosis coli or ischaemic colitis? That is the question

artículo científico publicado en 2015

Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC

artículo científico publicado en 2020

Non-coding RNAs in lung cancer

artículo científico publicado en 2014

Osimertinib

artículo científico publicado en 2018

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Osimertinib for -mutant non-small cell lung cancer: place in therapy and future perspectives

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

artículo científico publicado en 2017

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

artículo científico publicado en 2020

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer

artículo científico publicado en 2015

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

artículo científico publicado en 2018

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

artículo científico publicado en 2019

Reply to J. Delyon et al

scientific article published on 09 October 2019

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression

scientific article published on 27 February 2019

Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)

artículo científico publicado en 2019

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

artículo científico publicado en 2016

Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication

artículo científico publicado en 2020

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

artículo científico publicado en 2017

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence

scientific article published on 04 December 2018

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

artículo científico publicado en 2015

The safety of nivolumab for the treatment of advanced non-small cell lung cancer

artículo científico publicado en 2016

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

scholarly article by Biagio Ricciuti et al published 28 March 2019 in Journal for Immunotherapy of Cancer

miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.

artículo científico publicado en 2015

Lista de obras de Biagio Ricciuti

A comparison of mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient

Emerging Biomarkers in the Era of Personalized Cancer Medicine

Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report.

Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.

Future options for ALK-positive non-small cell lung cancer.

High density lipoprotein cholesterol and cancer: Marker or causative?

High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art.

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Melanosis coli or ischaemic colitis? That is the question

Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC

Non-coding RNAs in lung cancer

Osimertinib

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer

Osimertinib for -mutant non-small cell lung cancer: place in therapy and future perspectives

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

Reply to J. Delyon et al

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression

Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

The safety of nivolumab for the treatment of advanced non-small cell lung cancer

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.